Barclays PLC Verona Pharma PLC Transaction History
Barclays PLC
- $357 Billion
- Q4 2024
A detailed history of Barclays PLC transactions in Verona Pharma PLC stock. As of the latest transaction made, Barclays PLC holds 5,313 shares of VRNA stock, worth $333,125. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,313
Previous 359
1379.94%
Holding current value
$333,125
Previous $10,000
2360.0%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding VRNA
# of Institutions
219Shares Held
67.5MCall Options Held
1.4MPut Options Held
299K-
Perceptive Advisors LLC New York, NY6.39MShares$401 Million9.9% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$350 Million18.53% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$212 Million9.42% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.13MShares$196 Million2.79% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx3.13MShares$196 Million2.81% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $3.82B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...